Literature DB >> 12105203

Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis.

Monika Weingärtner1, Daniela Siegmund, Ulrich Schlecht, Mariola Fotin-Mleczek, Peter Scheurich, Harald Wajant.   

Abstract

The heat shock protein 90 (Hsp-90) inhibitor, geldanamycin, and the proteasome inhibitor, MG-132, both inhibited tumor necrosis factor receptor 1 (TNF-R1)- but not TRAIL-induced apoptosis in Kym-1 cells, suggesting that TNF-R1-induced cell death is dependent on NF-kappaB activation in this model. Triggering of TNF-R1 by agonistic antibodies led to cell-type specific induction of endogenous TNF and apoptosis, the latter of which was abrogated by neutralizing TNF specific antibodies. TNF-R1-stimulated cells expressed TNF mainly in a cell-associated form, suggesting that the endogenously produced TNF act in its membrane-bound form. Geldanamycin failed to inhibit apoptosis induction by a combination of agonistic TNF-R1- and TNF-R2-specific antibodies, indicating that both TNF receptors co-operate in TNF-R1-triggered apoptosis in Kym-1 cells. Thus, TNF-R1 stimulation can elicit a strong and rapid apoptotic response via induction of membrane TNF and subsequent cooperation of TNF-R1 and TNF-R2. Moreover, we give evidence that this mechanism circumvents the need of the prolonged presence of exogenous soluble TNF for TNF-R1-mediated apoptosis induction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105203     DOI: 10.1074/jbc.M205149200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Autoamplification of tumor necrosis factor-alpha: a potential mechanism for the maintenance of elevated tumor necrosis factor-alpha in male but not female obese mice.

Authors:  Jaap G Neels; Manjula Pandey; Gökhan S Hotamisligil; Fahumiya Samad
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

2.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

3.  Functional dichotomy of A20 in apoptotic and necrotic cell death.

Authors:  Peter Storz; Heike Döppler; Christiane Ferran; Shane T Grey; Alex Toker
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

4.  IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1.

Authors:  M D Faye; S T Beug; T E Graber; N Earl; X Xiang; B Wild; S Langlois; J Michaud; K N Cowan; R G Korneluk; M Holcik
Journal:  Oncogene       Date:  2014-04-07       Impact factor: 9.867

5.  Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis.

Authors:  Daniela Siegmund; Juliane Kums; Martin Ehrenschwender; Harald Wajant
Journal:  Cell Death Dis       Date:  2016-09-22       Impact factor: 8.469

Review 6.  Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer.

Authors:  Harald Wajant; Andreas Beilhack
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

7.  Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist.

Authors:  Kirstin Kucka; Isabell Lang; Tengyu Zhang; Daniela Siegmund; Juliane Medler; Harald Wajant
Journal:  Cell Death Dis       Date:  2021-04-06       Impact factor: 8.469

8.  Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.

Authors:  Christine C Dobson; Thet Naing; Shawn T Beug; Mame D Faye; Janelle Chabot; Martin St-Jean; Danielle E Walker; Eric C LaCasse; David F Stojdl; Robert G Korneluk; Martin Holcik
Journal:  Oncotarget       Date:  2017-01-10

9.  MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma.

Authors:  Xing Wang; Yu-Qiang Shan; Qing-Quan Tan; Chun-Lu Tan; Hao Zhang; Jin-Heng Liu; Neng-Wen Ke; Yong-Hua Chen; Xu-Bao Liu
Journal:  Cancer Cell Int       Date:  2020-02-28       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.